Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 15Carcinoma, Hepatocellular 13Urinary Bladder Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 9Neoplasms 8Carcinoma, Transitional Cell 8Stomach Neoplasms 7Neoplasm Metastasis 7Breast Neoplasms 6Triple Negative Breast Neoplasms 5Melanoma 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Carcinoma, Neuroendocrine 3Urethral Neoplasms 2Ureteral Neoplasms 2Turcot syndrome 2Solid Tumors 2Rectal Neoplasms 2Pancreatic Neoplasms 2Nasopharyngeal Carcinoma 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Glioma 2

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Metastatic Breast Cancer × atezolizumab × Clear all
NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡